Clinical Trials Logo

Filter by:
NCT ID: NCT06043024 Recruiting - Clinical trials for Temporomandibular Joint Disorders

Characteristics of Cytokine Response in Patients With Temporomandibular Disorders Treated With Occlusal Splint Therapy

Start date: August 16, 2023
Phase: N/A
Study type: Interventional

The goal of this intervention study is to determine the effect of occlusal splint (OS) therapy on the concentration of inflammatory cytokines in serum and gingival crevicular fluid (GCF) in patients with temporomandibular disorders (TMDs). Aims are: - to determine cytokines level in GCF and serum before and after OS therapy - to determine the degree of psychosocial dysfunction and oral health-related quality of life before and after OS therapy - investigate the correlation between cytokines level in GCF and serum - to determine the effect of OS on treatment outcomes, pain intensity, dysfunction, and psychosocial status of patients with painful TMD. Participants will be asked to complete self-assessment questionnaires, and GCF and blood samples will be collected before beginning of the OS therapy and at follow-up examinations one month and two months after.

NCT ID: NCT06021743 Recruiting - Sepsis Clinical Trials

The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis

SepsisFAT
Start date: January 1, 2022
Phase:
Study type: Observational

The impact of the complex liver immunological network on sepsis outcome is largely unknown. Steatotic liver disease (SLD) is the most common chronic liver disease with prevalence of 25% in European countries. The question remains whether patients with SLD are more prone to bacterial infections and what is the impact of persistent liver inflammation to the systemic response to infection, sepsis course and outcomes. Semaphorins are a large family of secreted and membrane-bound biological response modifiers present in many organ systems that are associated with SLD and development of fibrosis, but also might regulate systemic immune responses in sepsis. This study will investigate the association of semaphorins with sepsis outcomes in patients with SLD.

NCT ID: NCT05998746 Recruiting - Frailty Clinical Trials

Comparison of ASA and CFS in Anesthesiology

CACA
Start date: July 17, 2023
Phase:
Study type: Observational [Patient Registry]

In addition to the regular ASA classification, patients would also be assigned the Clinical frailty scale (CFS) during preoperative examinations in anesthesiology clinics. The aim is to compare the usefulness of ASA and CFS categorization for predicting perioperative and postoperative complications and length of postoperative stay in elective surgeries.

NCT ID: NCT05992389 Recruiting - Asthma in Children Clinical Trials

Evidence Driven Indoor Air Quality Improvement

Start date: April 3, 2023
Phase:
Study type: Observational

The aim is to identify the underlying disease mechanisms driving specific asthma phenotypes as well as certain disease outcomes and their relation to impaired indoor air quality. This may also help in underpinning specific target mechanisms in order to personalize and improve current treatment options in childhood asthma and develop more successful prevention strategies. This will be done by combining data from detailed clinical phenotyping with multiple -omics data.

NCT ID: NCT05990049 Recruiting - Pain, Postoperative Clinical Trials

Hyaluronic Acid and Free Gingival Graft Healing

Start date: March 1, 2023
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the impact of locally applied hyaluronic acid on free gingival graft wound bed healing and palatal donor site wound healing. Forty subjects will be randomly divided in two separate groups. Test group will be treated with hyaluronic acid during the procedure and the control group without. Periodontal parameters and other clinical measurements will be taken on baseline, 7 days postoperative, 14 days postoperative, 1 month, 3 months and 6 months postoperative.

NCT ID: NCT05980663 Recruiting - Obesity Clinical Trials

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet in Obese Participants With Asthma

Start date: January 17, 2023
Phase: N/A
Study type: Interventional

Randomized stratified controlled clinical study for evaluate the effectiveness of a diet program designed for reduce body weight through standard and innovative products that are a substitute meal for weight management in a reduction diet in obese participants with asthma.

NCT ID: NCT05977842 Recruiting - Clinical trials for Coronary Artery Disease

Drug-coated Balloon in de Novo Chronic Total Occlusions

CTO-DENOVO
Start date: January 31, 2024
Phase:
Study type: Observational

The CTO-DENOVO study is a multicenter registry of consecutive patients with de novo CTO undergoing successful CTO recanalization with the use of DCB-only strategy. The primary endpoint is target lesion failure at 6 months. The secondary endpoints are: 1) late lumen loss on follow-up angiography, and 2) minimal lumen area on follow-up intravascular ultrasound.

NCT ID: NCT05971875 Recruiting - Clinical trials for Minimally Invasive Surgery

RCT on 3 Types of Hysterectomy

VANOLAH
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

A randomized controlled trial comparing the vaginal, vNOTES ( vaginal natural orifice transluminal surgery) or laparoscopic approach for hysterectomy in women with benign gynaecological disease

NCT ID: NCT05971693 Recruiting - Atrial Fibrillation Clinical Trials

A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator

Omny-IRE
Start date: September 12, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE Bi-directional catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF).

NCT ID: NCT05966480 Recruiting - SLE Clinical Trials

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

LUMUS
Start date: June 26, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.